Surgical Site Infections Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest Drug Approvals, Emerging Drugs, and Growth Prospects | Johnson & Johnson, 3M, Belimed AG, Becton, Dickinson and Company, Kimberly-Clark Corporation,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Surgical Site Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Surgical Site Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Surgical Site Infections Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Surgical Site Infections Market.

The Surgical Site Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Surgical Site Infections Pipeline Report: https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Surgical Site Infections treatment therapies with a considerable amount of success over the years.
• Surgical Site Infections companies working in the treatment market are Covira Surgical, Sonoran Biosciences, Eupraxia Pharmaceuticals, Destiny Pharma, POLYPID, and others, are developing therapies for the Surgical Site Infections treatment
• Emerging Surgical Site Infections therapies in the different phases of clinical trials are- CS-0003, SBG003, EP 201, XF-73, D-PLEX, and others are expected to have a significant impact on the Surgical Site Infections market in the coming years.
• In January 2023, D-PLEX100 has received a favourable regulatory update from PolyPid Ltd. for the treatment of surgery site infections (SSIs) at the abdomen colorectal region. The US Food and Drug Administration (FDA) and the Company recently held a type D meeting to discuss the SHIELD I Phase III data, and as a result, the Company now has clarity regarding the regulatory road towards a prospective New Drug Application (NDA) submission
• In August 2022, In order to improve surgical outcomes, late-stage biopharma company PolyPid Ltd. ("PolyPid") and ADVANZ PHARMA Corp. Limited entered into an exclusive licencing agreement. As a result, ADVANZ PHARMA will have the sole right to commercialise PolyPid's lead drug candidate, D-PLEX100, for the prevention of surgical site infections ("SSIs") in abdominal and cardiac surgeries throughout Europe
• In December 2020, In order to evaluate the effectiveness and safety of D-PLEX administered concurrently with standard of care (SoC), compared to a SoC treated control arm, in the prevention of post abdominal surgery incisional infection, POLYPID started a Phase III prospective, multinational, multicenter, randomised, controlled, two-arm, double blind study

Surgical Site Infections Overview
Surgical site infections (SSIs) are defined as infections that affect either the incision or deep tissue at the operation site and happen up to 30 days following surgery (or up to one year after surgery in patients receiving implants). SSIs continue to be a serious clinical issue despite advancements in prevention because they are linked to significant mortality and morbidity and place a heavy burden on the healthcare system's resources.

Get a Free Sample PDF Report to know more about Surgical Site Infections Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Surgical Site Infections Drugs Under Different Phases of Clinical Development Include:
• CS-0003: Covira Surgical
• SBG003: Sonoran Biosciences
• EP 201: Eupraxia Pharmaceuticals
• XF-73: Destiny Pharma
• D-PLEX: POLYPID

Surgical Site Infections Route of Administration
Surgical Site Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Surgical Site Infections Molecule Type
Surgical Site Infections Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Surgical Site Infections Pipeline Therapeutics Assessment
• Surgical Site Infections Assessment by Product Type
• Surgical Site Infections By Stage and Product Type
• Surgical Site Infections Assessment by Route of Administration
• Surgical Site Infections By Stage and Route of Administration
• Surgical Site Infections Assessment by Molecule Type
• Surgical Site Infections by Stage and Molecule Type
DelveInsight's Surgical Site Infections Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Surgical Site Infections product details are provided in the report. Download the Surgical Site Infections pipeline report to learn more about the emerging Surgical Site Infections therapies at:
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Surgical Site Infections Therapeutics Market include:
Key companies developing therapies for Surgical Site Infections are - Johnson & Johnson, 3M, Belimed AG, Becton, Dickinson and Company, Kimberly-Clark Corporation, Getinge Group, Steris Corporation, Sotera Health, bioMerieux SA, and others.

Surgical Site Infections Pipeline Analysis:
The Surgical Site Infections pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Surgical Site Infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Surgical Site Infections Treatment.
• Surgical Site Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Surgical Site Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Surgical Site Infections market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Surgical Site Infections drugs and therapies-
https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Surgical Site Infections Pipeline Market Drivers
• Rising number of surgeries and the growing geriatric population, increasing concern about hospital acquired infections along with rising incidences of hospital-acquired infections are some of the important factors that are fueling the Surgical Site Infections Market.

Surgical Site Infections Pipeline Market Barriers
• However, lack of awareness regarding infection control measures, difficulty in identifying the site of infection and other factors are creating obstacles in the Surgical Site Infections Market growth.

Scope of Surgical Site Infections Pipeline Drug Insight
• Coverage: Global
• Key Surgical Site Infections Companies: Covira Surgical, Sonoran Biosciences, Eupraxia Pharmaceuticals, Destiny Pharma, POLYPID, and others
• Key Surgical Site Infections Therapies: CS-0003, SBG003, EP 201, XF-73, D-PLEX, and others
• Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies
• Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers

Request for Sample PDF Report for Surgical Site Infections Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents

1. Surgical Site Infections Report Introduction
2. Surgical Site Infections Executive Summary
3. Surgical Site Infections Overview
4. Surgical Site Infections- Analytical Perspective In-depth Commercial Assessment
5. Surgical Site Infections Pipeline Therapeutics
6. Surgical Site Infections Late Stage Products (Phase II/III)
7. Surgical Site Infections Mid Stage Products (Phase II)
8. Surgical Site Infections Early Stage Products (Phase I)
9. Surgical Site Infections Preclinical Stage Products
10. Surgical Site Infections Therapeutics Assessment
11. Surgical Site Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Surgical Site Infections Key Companies
14. Surgical Site Infections Key Products
15. Surgical Site Infections Unmet Needs
16 . Surgical Site Infections Market Drivers and Barriers
17. Surgical Site Infections Future Perspectives and Conclusion
18. Surgical Site Infections Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Surgical Site Infections Market https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Surgical Site Infections-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Surgical Site Infections Epidemiology https://www.delveinsight.com/report-store/surgical-site-infections-ssi-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Surgical Site Infections Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.